Ophtalmologie. Blocage des cytokines et chemokines: nouvelles perspectives de traitement. [New therapies in ophthalmology: inhibitors of cytokines and chemokines: new treatment perspectives]

Détails

ID Serval
serval:BIB_841E13D79990
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Ophtalmologie. Blocage des cytokines et chemokines: nouvelles perspectives de traitement. [New therapies in ophthalmology: inhibitors of cytokines and chemokines: new treatment perspectives]
Périodique
Revue Médicale Suisse
Auteur(s)
Guex-Crosier  Y., Zografos  L.
ISSN
1660-9379 (Print)
Statut éditorial
Publié
Date de publication
01/2005
Volume
1
Numéro
2
Pages
140-1
Notes
English Abstract
Journal Article --- Old month value: Jan 12
Résumé
Anti-TNF-alpha (infliximab and etanercept) are potent, selective inhibitors of the inflammatory cascade. They have been widely used in the therapy of rheumatoid arthritis, Crohn's disease and psoriasis. Their efficacy in ophthalmology has been recently proven. The wide use of cytokines inhibitors could also be very useful in the therapy of neovessels in macular degeneration age-related, since the role of inflammation in the proliferation of neovessels has been recently discovered.
Mots-clé
Chemokines/antagonists & inhibitors Cytokines/antagonists & inhibitors Eye Diseases/*drug therapy Humans Tumor Necrosis Factor-alpha/*antagonists & inhibitors
Pubmed
Création de la notice
28/01/2008 14:10
Dernière modification de la notice
03/03/2018 18:54
Données d'usage